A Phase 2 Multicenter, Double-blind, Randomized, Adjunctive, Placebo-controlled Trial With an Open-label Extension to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Trial Profile

A Phase 2 Multicenter, Double-blind, Randomized, Adjunctive, Placebo-controlled Trial With an Open-label Extension to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors SK Life Science
  • Most Recent Events

    • 21 Sep 2016 Status changed from completed to active, no longer recruiting.
    • 21 Sep 2016 Planned End Date changed from 1 Jul 2013 to 1 Dec 2018.
    • 21 Apr 2016 Pooled analysis of seizure-free rates of 2 studies including this trial and another study (see CTP 700233519) were presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top